Ribonuclease-activated cancer prodrug

ACS Medicinal Chemistry Letters

Volumn 3, Issue 4, 2012, Pages 268-272

  Ellis, Gregory A ^a   McGrath, Nicholas A ^a   Palte, Michael J ^a   Raines, Ronald T ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

4 hydroxytamoxifen; human pancreatic ribonuclease; pharmacokinetics; plasma; tamoxifen; timed release

Indexed keywords

AFIMOXIFENE; PANCREATIC RIBONUCLEASE; PRODRUG; UNCLASSIFIED DRUG; URIDINE 3' (4 HYDROXYTAMOXIFEN PHOSPHATE);

ARTICLE; CELL PROLIFERATION; DRUG ACTIVATION; DRUG ACTIVITY; DRUG HALF LIFE; DRUG RELEASE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 84859773889     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml2002554     Document Type: Article

References (61)

1. Wang, B.; Siahaan, T.; Soltero, R. Drug Delivery: Principles and Applications; John Wiley & Sons: Hoboken, NJ, 2005.
2. Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh, D.; Jarvinen, T.; Savolainen, J. Prodrugs: Design and clinical applications Nat. Rev. Drug Discovery 2008, 7, 255-270 (Pubitemid 351324639)
3. Gennaro, A. R. Remington: The Science and Practice of Pharmacy, 21 st ed.; Lippincott Williams & Wilkins: Baltimore, MD, 2005.
4. Kratz, F.; Muller, I. A.; Ryppa, C.; Warnecke, A. Prodrug strategies in anticancer chemotherapy ChemMedChem 2008, 3, 20-53
5. Langer, R. New methods of drug delivery Science 1990, 249, 1527-1533
6. Testa, B.; Mayer, J. M. Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology; Wiley-VCH: Zürich, Switzerland, 2003.
7. Brown, D. M. Drug Delivery Systems in Cancer Therapy; Humana Press: Totowa, NJ, 2004.
8. Sorrentino, S. The eight human "canonical" ribonucleases: Molecular diversity, catalytic properties, and special biological actions of the enzyme proteins FEBS Lett. 2010, 584, 2194-2200
9. Su, A. I.; Wiltshire, T.; Batalov, S.; Lapp, H.; Ching, K. A.; Block, D.; Zhang, J.; Soden, R.; Hayakawa, M.; Kreiman, G.; Cooke, M. P.; Walker, J. R.; Hogenesch, J. B. A gene atlas of the mouse and human protein-encoding transcriptomes Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 6062-6067 (Pubitemid 38520528)
10. The ribonucleolytic activity in serum is attributable to RNase 1. Its concentration there is 156 units/mL with 1 unit of activity arising from 2.6 ng of enzyme. Weickmann, J. L.; Olson, E. M.; Glitz, D. G. Immunological assay of pancreatic ribonuclease in serum as an indicator of pancreatic cancer Cancer Res. 1984, 44, 1682-1687 (Pubitemid 14125864)
11. Also see Landré, J. B. P.; Hewett, P. W.; Olivot, J.-M.; Friedl, P.; Sachinidis, A.; Moenner, M. Human endothelial cells selectively express large amounts of pancreatic-type ribonuclease (RNase 1) J. Cell. Biochem. 2002, 86, 540-552 (Pubitemid 36076171)
12. Raines, R. T. Ribonuclease A. Chem. Rev. 1998, 98, 1045-1065 (Pubitemid 128632236)
13. Cuchillo, C. M.; Nogués, M. V.; Raines, R. T. Bovine pancreatic ribonuclease: Fifty years of the first enzymatic reaction mechanism Biochemistry 2011, 50, 7835-7841
14. Markham, R.; Smith, J. D. The structure of ribonucleic acids. 1. Cyclic nucleotides produced by ribonuclease and by alkaline hydrolysis Biochem. J. 1952, 52, 552-557
15. Cuchillo, C. M.; Parés, X.; Guasch, A.; Barman, T.; Travers, F.; Nogués, M. V. The role of 2′,3′-cyclic phosphodiesters in the bovine pancreatic ribonuclease A catalysed cleavage of RNA: Intermediates or products? FEBS Lett. 1993, 333, 207-210 (Pubitemid 23323983)
16. Thompson, J. E.; Venegas, F. D.; Raines, R. T. Energetics of catalysis by ribonucleases: Fate of the 2′,3′-cyclic phosphodiester intermediate Biochemistry 1994, 33, 7408-7414 (Pubitemid 24208781)
17. Davis, A. M.; Regan, A. C.; Williams, A. Experimental charge measurement at leaving oxygen in the bovine ribonuclease A catalyzed cyclization of uridine 3′-phosphate aryl esters Biochemistry 1988, 27, 9042-9047
18. Witmer, M. R.; Falcomer, C. M.; Weiner, M. P.; Kay, M. S.; Begley, T. P.; Ganem, B.; Scheraga, H. A. U-3′-BCIP: A chromogenic substrate for the detection of RNase A in recombinant DNA expression systems Nucleic Acids Res. 1991, 19, 1-4 (Pubitemid 21912646)
19. Thompson, J. E.; Raines, R. T. Value of general acid-base catalysis to Ribonuclease A J. Am. Chem. Soc. 1994, 116, 5467-5468
20. Stowell, J. K.; Widlanski, T. S.; Kutateladze, T. G.; Raines, R. T. Mechanism-based inactivation of ribonuclease A J. Org. Chem. 1995, 60, 6930-6936
21. Taylorson, C. J.; Eggelte, H. J.; Tarragona-Fiol, A.; Rabin, B. R.; Boyle, F. T.; Hennam, J. F.; Blakey, D. C.; Marsham, P. R.; Heaton, D. W.; Davies, D. H.; Slater, A. M.; Hennequin, L. F. A. Chemical compounds. U.S. Patent No. 5985281, 1999.
22. Beaucage, S. L.; Caruthers, M. H. Deoxynucleoside phosphoramidites-A new class of key intermediates for deoxypolynucleotide synthesis Tetrahedron Lett. 1981, 22, 1859-1862
23. Caruthers, M. H. A brief review of DNA and RNA chemical synthesis Biochem. Soc. Trans. 2011, 39, 575-580
24. Stella, V. J.; Nti-Addae, K. W. Prodrug strategies to overcome poor water solubility Adv. Drug Delivery Rev. 2007, 59, 677-94 (Pubitemid 47285410)
25. Wagner, C. R.; Iyer, V. V.; McIntee, E. J. Pronucleotides: Toward the in vivo delivery of antiviral and anticancer nucleotides Med. Res. Rev. 2000, 20, 417-51
26. Micklefield, J. Backbone modification of nucleic acids: Synthesis, structure and therapeutic applications Curr. Med. Chem. 2001, 8, 1157-79 (Pubitemid 32655075)
27. Schultz, C. Prodrugs of biologically active phosphate esters Bioorg. Med. Chem. 2003, 11, 885-898 (Pubitemid 36287048)
28. Anastasi, C.; Quelever, G.; Burlet, S.; Garino, C.; Souard, F.; Kraus, J. L. New antiviral nucleoside prodrugs await application Curr. Med. Chem. 2003, 10, 1825-43 (Pubitemid 37038603)
29. Venturoli, D.; Rippe, B. Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: Effects of molecular size, shape, charge, and deformability Am. J. Physiol.-Renal 2005, 288, F605-F613 (Pubitemid 40381726)
30. Owens, D. E., 3rd; Peppas, N. A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles Int. J. Pharm. 2006, 307, 93-102 (Pubitemid 41773257)
31. Hecker, S. J.; Erion, M. D. Prodrugs of phosphates and phosphonates J. Med. Chem. 2008, 51, 2328-2345 (Pubitemid 351628494)
32. Khandazhinskaya, A.; Matyugina, E.; Shirokova, E. Anti-HIV therapy with AZT prodrugs: AZT phosphonate derivatives, current state and prospects Expert Opin. Drug Metab. Toxicol. 2011, 6, 701-714
33. Desta, Z.; Ward, B. A.; Soukhova, N. V.; Flockhart, D. A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6 J. Pharmacol. Exp. Ther. 2004, 310, 1062-1075 (Pubitemid 39108928)
34. Coezy, E.; Borgna, J. L.; Rochefort, H. Tamoxifen and metabolites in MCF7 cells: Correlation between binding to estrogen receptor and inhibition of cell growth Cancer Res. 1982, 42, 317-323 (Pubitemid 12207285)
35. O'Regan, R. M.; Jordan, V. C. The evolution of tamoxifen therapy in breast cancer: Selective oestrogen-receptor modulators and downregulators Lancet Oncol. 2002, 3, 207-214 (Pubitemid 34441026)
36. Powles, T. J. Anti-oestrogenic chemoprevention of breast cancer-the need to progress Eur. J. Cancer 2003, 39, 572-579 (Pubitemid 36287368)
37. Fisher, B.; Costantino, J. P.; Wickerham, D. L.; Cecchini, R. S.; Cronin, W. M.; Robidoux, A.; Bevers, T. B.; Kavanah, M. T.; Atkins, J. N.; Margolese, R. G.; Runowicz, C. D.; James, J. M.; Ford, L. G.; Wolmark, N. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study J. Natl. Cancer Inst. 2005, 97, 1652-1662 (Pubitemid 41672231)
38. Bergman, L.; Beelen, M. L.; Gallee, M. P.; Hollema, H.; Benraadt, J.; van Leeuwen, F. E. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive cancer centres' ALERT group. Assessment of liver and endometrial cancer risk following tamoxifen Lancet 2000, 356, 881-887
39. Decensi, A.; Robertson, C.; Viale, G.; Pigatto, F.; Johansson, H.; Kisanga, E. R.; Veronesi, P.; Torrisi, R.; Cazzaniga, M.; Mora, S.; Sandri, M. T.; Pelosi, G.; Luini, A.; Goldhirsch, A.; Lien, E. A.; Veronesi, U. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers J. Natl. Cancer Inst. 2003, 95, 779-790 (Pubitemid 36798424)
40. Vitseva, O.; Flockhart, D. A.; Jin, Y.; Varghese, S.; Freedman, J. E. The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates J. Pharmacol. Exp. Ther. 2005, 312, 1144-1150 (Pubitemid 40293775)
41. Veronesi, U.; Maisonneuve, P.; Decensi, A. Tamoxifen: An enduring star J. Natl. Cancer Inst. 2007, 99, 258-260 (Pubitemid 47078726)
42. Layek, B.; Mukherjee, B. Tamoxifen citrate encapsulated sustained release liposomes: Preparation and evaluation of physicochemical properties Sci. Pharm. 2010, 78, 507-515
43. Andresen, T. L.; Jensen, S. S.; Jorgensen, K. Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release Prog. Lipid Res. 2005, 44, 68-97 (Pubitemid 40313220)
44. Katzenellenbogen, J. A.; Carlson, K. E.; Katzenellenbogen, B. S. Facile geometric isomerization of phenolic non-steroidal estrogens and antiestrogens: Limitations to the interpretation of experiments characterizing the activity of individual isomers J. Steroid Biochem. 1985, 22, 589-596 (Pubitemid 15003142)
45. Murphy, C. S.; Langan-Fahey, S. M.; McCague, R.; Jordan, V. C. Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro Mol. Pharmacol. 1990, 38, 737-743
46. Hayakawa, Y.; Kawai, R.; Hirata, A.; Sugimoto, J. I.; Kataoka, M.; Sakakura, A.; Hirose, M.; Noyori, R. Acid/azole complexes as highly effective promoters in the synthesis of DNA and RNA oligomers via the phosphoramidite method J. Am. Chem. Soc. 2001, 123, 8165-8176 (Pubitemid 32916392)
47. Calculator Plugins were used for structure property prediction and calculation. Marvin 5.4.1.1; ChemAxon: Budapest, Hungary, 2011.
48. Kelemen, B. R.; Klink, T. A.; Behlke, M. A.; Eubanks, S. R.; Leland, P. A.; Raines, R. T. Hypersensitive substrate for ribonucleases Nucleic Acids Res. 1999, 27, 3696-3701 (Pubitemid 29435750)
49. Smith, B. D.; Soellner, M. B.; Raines, R. T. Potent inhibition of ribonuclease A by oligo(vinylsulfonic acid) J. Biol. Chem. 2003, 278, 20934-20938 (Pubitemid 36806401)
50. Johnson, R. J.; McCoy, J. G.; Bingman, C. A.; Phillips, G. N., Jr.; Raines, R. T.; Phillips, G. N. Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein J. Mol. Biol. 2007, 368, 434-449 (Pubitemid 46483483)
51. Serum contains both contaminating ribonucleases and albumin, which binds and thus sequesters HT. Bourassa, P.; Dubeau, S.; Maharvi, G. M.; Fauq, A. H.; Thomas, T. J.; Tajmir-Riahi, H. A. Binding of antitumor tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen to human serum albumin Biochimie 2011, 93, 1089-1101
52. Thompson, J. E.; Kutateladze, T. G.; Schuster, M. C.; Venegas, F. D.; Messmore, J. M.; Raines, R. T. Limits to catalysis by ribonuclease A Bioorg. Chem. 1995, 23, 471-481 (Pubitemid 26027357)
53. Sorrentino, S.; Libonati, M. Human pancreatic-type and nonpancreatic-type ribonucleases: A direct side-by-side comparison of their catalytic properties Arch. Biochem. Biophys. 1994, 312, 340-348
54. Fell, R.; Brocard, J.; Mascrez, B.; LeMeur, M.; Metzger, D.; Chambon, P. Ligand-activated site-specific recombination in mice Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 10887-10890 (Pubitemid 26333086)
55. Hayashi, S.; McMahon, A. P. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: A tool for temporally regulated gene activiation/inactivation in the mouse Dev. Biol. 2002, 244, 305-318 (Pubitemid 34450645)
56. Weickmann, J. L.; Olson, E. M.; Glitz, D. G. Immunological assay of pancreatic ribonuclease in serum as an indicator of pancreatic cancer Cancer Res. 1984, 44, 1682-1687 (Pubitemid 14125864)
57. Potenza, N.; Salvatore, V.; Migliozzi, A.; Martone, V.; Nobile, V.; Russo, A. Hybridase activity of human ribonuclease-1 revealed by a real-time fluorometric assay Nucleic Acids Res. 2006, 34, 2906-2913 (Pubitemid 44540418)
58. Munitz, A.; Levi-Schaffer, F. Eosinophils: 'New' roles for 'old' cells Allergy 2004, 59, 268-275 (Pubitemid 38339842)
59. Cormier, S. A.; Taranova, A. G.; Bedient, C.; Nguyen, T.; Protheroe, C.; Pero, R.; Dimina, D.; Ochkur, S. I.; O'Neill, K.; Colbert, D.; Lombari, T. R.; Constant, S.; McGarry, M. P.; Lee, J. J.; Lee, N. A. Pivotal advance: Eosinophil infiltration of solid tumors is an early and persistent inflammatory host response J. Leukocyte Biol. 2006, 79, 1131-1139 (Pubitemid 44835546)
60. Lotfi, R.; Lee, J. J.; Lotze, M. T. Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): Role in the inflammatory response within tumors J. Immunother. 2007, 30, 16-28 (Pubitemid 46052200)
61. Bosslet, K.; Straub, R.; Blumrich, M.; Czech, J.; Gerken, M.; Sperker, B.; Kroemer, H. K.; Gesson, J. P.; Koch, M.; Monneret, C. Elucidation of the mechanism enabling tumor selective prodrug monotherapy Cancer Res. 1998, 58, 1195-1201 (Pubitemid 28183208)